(Q39667736)

English

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents

scientific article published on September 1, 2003

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL) for children and adolescents (English)

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Efficacy and tolerability of short-term specific immunotherapy with pollen allergoids adjuvanted by monophosphoryl lipid A (MPL®) for children and adolescents (Spanish)

1 reference

10.1016/S0301-0546(03)79195-2

https://api.crossref.org/works/10.1016/S0301-0546(03)79195-2

24 March 2024

0 references

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

allergen immunotherapy

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14572416

24 March 2024

1 reference

10.1016/S0301-0546(03)79195-2

https://api.crossref.org/works/10.1016/S0301-0546(03)79195-2

24 March 2024

author name string

K. J. Drachenberg

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14572416

24 March 2024

M. Heinzkill

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14572416

24 March 2024

E. Urban

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14572416

24 March 2024

S. R. Woroniecki

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14572416

24 March 2024

language of work or name

1 reference

National Center for Biotechnology Information

PubMed publication ID

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=14572416

24 March 2024

publication date

1 September 2003

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

full work available at URL

https://api.elsevier.com/content/article/PII:S0301054603791952?httpAccept=text/xml

1 reference

10.1016/S0301-0546(03)79195-2

https://api.crossref.org/works/10.1016/S0301-0546(03)79195-2

24 March 2024

https://api.elsevier.com/content/article/PII:S0301054603791952?httpAccept=text/plain

1 reference

10.1016/S0301-0546(03)79195-2

https://api.crossref.org/works/10.1016/S0301-0546(03)79195-2

24 March 2024

Allergologia et Immunopathologia

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

31

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

5

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

270-277

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Immunological mechanisms operative in allergen-specific immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A Th1-inducing adjuvant, MPL, enhances antibody profiles in experimental animals suggesting it has the potential to improve the efficacy of allergy vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Allergen immunotherapy: therapeutic vaccines for allergic diseases. Geneva: January 27-29 1997

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study).

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical modification of crude timothy grass pollen extract. II. Class and specificity of antibodies induced by chemically modified timothy grass pollen extract

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Chemical modification of crude timothy grass pollen extract. III. The effect of glutaraldehyde-induced aggregation on antigenic and immunogenic properties

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Review of L-tyrosine confirming its safe human use as an adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Safety evaluation of monophosphoryl lipid A (MPL): an immunostimulatory adjuvant.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Natural history of hay fever and pollen sensitization, and doctors' diagnosis of hay fever and pollen asthma in German schoolchildren

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany.

1 reference

https://api.crossref.org/works/10.1016%2FS0301-0546%2803%2979195-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Monophosphoryl lipid A as an adjuvant. Past experiences and new directions

2

1 reference

10.1016/S0301-0546(03)79195-2

https://api.crossref.org/works/10.1016/S0301-0546(03)79195-2

24 March 2024

Identifiers

10.1016/S0301-0546(03)79195-2

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

13 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39667736&oldid=2109526943"